STX8

Across TCGA pan-cancer cohorts, STX8 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated STX8 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher STX8 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated STX8 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

LUAD and PDAC are the cancer types where STX8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.409	0.941	.010	10	view →
PDAC	OS	Median	IV	0.836	0.491	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

STX8–LUAD (DFS)

Open the LUAD breakdown →